Can a phone app help cancer survivors sleep better?
NCT ID NCT03537963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a mobile health (mHealth) program designed to help people who have had a stem cell transplant for blood cancer get better sleep. Researchers wanted to see if the program was easy to use and if participants liked it. About 30 survivors, caregivers, and doctors gave feedback to help shape the program.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mHealth stepped-care intervention (mobile health program)
- What this could lead to
- If it works, this could point toward a simple, home-based way to improve sleep for stem cell transplant survivors.
- What could go wrong
- This is a very small, early feasibility study with only 30 participants. It focuses on whether people will use the program, not yet on whether it actually improves sleep.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
May 2018
- Finished
-
Apr 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: FOR QUALITATIVE INTERVIEWS PRE-TEST * HCT survivors: Potentially eligible patients will be approached in person during a routine outpatient appointment at Moffitt Cancer Center or via telephone. * Additional eligibility criteria for HCT survivors will require that participants have undergone an allogeneic HCT within the previous 6 months - 2 years for a hematologic malignancy and be reporting clinically significant sleep disturbance (≥ 4 on a scale of 0 - 10). * Caregivers of HCT survivors: Patient participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. * Adults ≥ 18 years old * Able to speak and read English * Able to provide informed consent * Have no documented or observable severe and untreated neurological or psychiatric disorders that would preclude participation (e.g., psychosis). * Clinicians: Eligible clinicians will be oncologists, nurses, or other clinicians at the Moffitt Cancer Center Blood and Marrow Transplant Program. FOR INTERVENTION GROUPS * Are ≥18 years of age * Have been diagnosed with a hematologic malignancy * Were discharged after allogeneic HCT within the previous 110 days (to allow for those who return to clinic within approximately 2 weeks of their planned 90-day clinic visit) * Are experiencing clinically significant sleep disturbance * Have never been diagnosed with nor are at high risk of sleep disorders that are unlikely to be ameliorated with behavioral treatment (e.g., obstructive sleep apnea, restless leg syndrome) as assessed using the Duke Structured Interview for Sleep Disorders * Are able to sign informed consent * Do not have any untreated or severe psychiatric or neurological disorders or other disabilities that would impair their ability to participate in this study. Exclusion Criteria: * Do not meet Inclusion Criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a sleep drug help cirrhosis patients rest and think clearer?
- Can a Platelet-Boosting drug speed recovery after stem cell transplant?
- Can regional data improve bone marrow transplant results for blood cancers?
- Could a frailty score predict which older cancer patients survive intensive care?
- Can a Phone-Based sleep program help dementia caregivers rest better?
- Why COVID-19 hits blood cancer patients harder: scientists map the immune clues